Uncategorized
Enrollment completed in Leber’s hereditary optic neuropathy trial
Enrollment has been completed in a phase 3 clinical trial of a treatment for Leber’s hereditary optic neuropathy, according to a press release from GenSight Biologics.The RESCUE randomized, double-masked, sham-controlled multicenter trial will evaluate a single intravitreal injection of GS010, designed to treat Leber’s hereditary optic neuropathy caused by a mutation in the ND4 gene, in 37 patients, the release said.